NEKTAR® NEW PATHWAYS TO SMARTER MEDICINE™ SITC 2019 Nektar Therapeutics Investor & Analyst Call November 10, 2019 This presentation includes forward-looking statements regarding Nektar's proprietary drug candidates, the timing of the start and conclusion of ongoing or planned clinical trials, the timing and outcome of regulatory decisions, and future availability of clinical trial data. Actual results could differ materially and these statements are subject to important risks detailed in Nektar's filings wi ...

Nektar Therapeutics (NASDAQ:NKTR) Q3 2019 Earnings Conference Call November 6, 2019 5:00 PM ET Company Participants Jennifer Ruddock - Head of Investor Relations Howard Robin - President & Chief Executive Officer Gil Labrucherie - Chief Operating Officer & Chief Financial Officer Jonathan Zalevsky - Head of Research & Development Conference Call Participants Chris Shibutani - Cowen Jessica Fye - JPMorgan Tyler Van Buren - Piper Jaffray Alex Lim - Mizuho George Farmer - BMO Capital Markets Gobind Singh - BMO ...

Nektar Therapeutics (NASDAQ:NKTR) Q2 2019 Earnings Conference Call August 8, 2019 5:00 PM ET Company Participants Jennifer Ruddock ??? Head of Investor Relations Howard Robin ??? President and CEO Gil Labrucherie ??? Chief Financial Officer Stephen Doberstein ??? Head of R&D Jonathan Zalevsky ??? Chief Scientific Officer Mary Tagliaferri ??? Chief Medical officer Conference Call Participants Chris Shibutani ??? Cowen Jessica Fye ??? JPMorgan Tyler Van Buren ??? Piper Jaffray Paul Choi ??? Goldman Sachs Alex ...

| --- | --- | --- | --- | |-------|-------|--------------|------------------------------------| | | | | | | | | | | | | | | | | | | 2019 EULAR | European Congress of Rheumatology | | | | Analyst Call | June 13, 2019 | | | | | | This presentation includes forward-looking statements regarding Nektar's proprietary drug candidates, the timing of the start and conclusion of ongoing or planned clinical trials, the timing and outcome of regulatory decisions, and future availability of clinical trial data. Actual r ...

Nektar Therapeutics (NASDAQ:NKTR) Q1 2019 Earnings Conference Call May 8, 2019 5:00 PM ET Company Participants Jennifer Ruddock - Senior Vice President of Investor Relations Howard Robin - President and Chief Executive Officer Gil Labrucherie - Senior Vice President and Chief Financial Officer Steven Doberstein - Head of R&D Jonathan Zalevsky - Chief Scientific Officer Mary Tagliaferri - Chief Medical Officer Conference Call Participants Chris Shibutani - Cowen Jessica Fye - JP Morgan George Farmer - BMO C ...

Nektar Therapeutics (NASDAQ:NKTR) Q4 2018 Earnings Conference Call February 28, 2019 5:00 PM ET Company Participants Jennifer Ruddock ??? Head-Investor Relations Howard Robin ??? President and Chief Executive Officer Mary Tagliaferri ??? Chief Medical Officer Gil Labrucherie ??? Chief Financial Officer Jonathan Zalevsky ??? Chief Scientific Officer Conference Call Participants Jessica Fye ??? JPMorgan Chris Shibutani ??? Cowen Paul Choi ??? Goldman Sachs George Farmer ??? BMO Capital Markets Alexander Dunca ...

| --- | --- | |-------|-----------------------------------| | | | | | 37th Annual | | | J.P. Morgan Healthcare Conference | | | Howard Robin | | | President & CEO | | | January 8, 2019 | 2 This presentation includes forward-looking statements regarding Nektar's proprietary drug candidates, the timing of the start and conclusion of ongoing or planned clinical trials, the timing and outcome of regulatory decisions, and future availability of clinical trial data. Actual results could differ materially and thes ...